Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02122952 · ClinicalTrials.gov registry record · Phase 1
Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1
A Phase 1 study, sponsored by Novartis Gene Therapies.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT02122952 is a Phase 1 study that has completed, run by Novartis Gene Therapies. The registered enrollment target is 15 participants.
The verdict
NCT02122952, a Phase 1 study, has completed, sponsored by Novartis Gene Therapies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of AVXS-101 as a treatment of spinal muscular atrophy Type 1 (SMN1).
Interventions
- BIOLOGICAL AVXS-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-05-05 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02122952
The ClinicalTrials.gov registry entry for NCT02122952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Gene Therapies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AVXS-101 is the first listed.
NCT02122952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02122952 about?
NCT02122952 is a clinical study titled "Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1". The purpose of this trial is to evaluate safety and efficacy of intravenous delivery of AVXS-101 as a treatment of spinal muscular atrophy Type 1 (SMN1).
What is the current status of trial NCT02122952?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2014-05-05. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT02122952?
The interventions under investigation include: AVXS-101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02122952?
This trial is sponsored by Novartis Gene Therapies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.